{
    "clinical_study": {
        "@rank": "45341", 
        "arm_group": {
            "arm_group_label": "Scar Revision", 
            "arm_group_type": "Experimental", 
            "description": "Caesarean Scar Revision using Lumenis UltraPulse Encore."
        }, 
        "brief_summary": {
            "textblock": "Ten (10) adult female subjects that had a caesarean surgery performed.Study will be\n      conducted in 1 site.\n\n      Each subject will receive three treatments on one area that was randomly chosen. The other\n      area will be left untreated and will serve as a control.\n\n      The objective is to Evaluate the clinical impact of UltraPulse fractional carbon dioxide\n      laser treatment on the appearance of a Caesarean Scar (CS) as compared to a similar\n      untreated scar side."
        }, 
        "brief_title": "Caesarean Scar Revision With the UltraPulse", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Scar Revision", 
        "condition_browse": {
            "mesh_term": "Cicatrix"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Females in good general health older than 22 years of age and younger than 55 years\n             of age.\n\n          2. Presenting with a caesarean scar mature and stable caesarean scar  (at least 1 year\n             post procedure).\n\n          3. At least six months following termination of breast feeding.\n\n          4. Willing to give and sign an informed consent form and a photographic release form.\n\n          5. Willing to comply with study dosing and complete the entire course of the study .\n\n          6. Performed negative pregnancy test.\n\n        Exclusion Criteria:\n\n          1. Active bacterial, fungal, or viral infection in the treatment area.\n\n          2. Active cold sores, or herpes in the treatment area.\n\n          3. Recent excessive exposure to sunlight or artificial UV light (e.g.: use of tanning\n             beds/booths and/or sunbathing) or expectations of tanning during the time of the\n             study .\n\n          4. History of or the presence of any skin condition/disease that might interfere with\n             the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema,\n             psoriasis).\n\n          5. Treatment with a systemic retinoid within the past year (e.g., Accutane\u00ae, Roche\n             Dermatologics).\n\n          6. History or presenting with a keloid scar.\n\n          7. Any current or recent treatment for cancer.\n\n          8. Any uncontrolled systemic disease. A potential subject in whom therapy for a systemic\n             disease is not yet stabilized will not be considered for entry into the study.\n\n          9. Significant history or current evidence of a medical, psychological or other disorder\n             that, in the investigator's opinion, would preclude enrollment into the study.\n\n         10. Previous laser treatments on the same scar at least 0.5 year prior to this\n             evaluation.\n\n         11. Subject planning any other cosmetic procedure to the study area during the study\n             period, other than the treatments that will be performed by the investigator .\n\n         12. Any other condition that may exclude patient for treatment per physician discretion.\n\n         13. Female subject who is pregnant, nursing an infant ."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "22 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02050126", 
            "org_study_id": "LUM-ABU-UP-12-02"
        }, 
        "intervention": {
            "arm_group_label": "Scar Revision", 
            "description": "Treatment using Lumenis UltraPulse Encore.", 
            "intervention_name": "Lumenis UltraPulse Encore.", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "contact": {
                "email": "mhaedersdal@dadlnet.dk", 
                "last_name": "Merete H\u00e6dersdal, overl\u00e6ge, dr. med., ph.d.", 
                "phone": "35 31 60 02"
            }, 
            "facility": {
                "address": {
                    "city": "K\u00f8benhavn", 
                    "country": "Denmark", 
                    "state": "Bispebjerg Bakke 23", 
                    "zip": "2400"
                }, 
                "name": "Dermato-venerologisk Afdeling D42"
            }, 
            "investigator": [
                {
                    "last_name": "Merete H\u00e6dersdal, overl\u00e6ge, dr. med., ph.d.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Katrine Lindeburg, l\u00e6ge", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "1", 
        "official_title": "Caesarean Scar Revision With the UltraPulse", 
        "overall_contact": {
            "last_name": "Merete H\u00e6dersdal, dr.med., ph.d", 
            "phone": "35 31 60 02"
        }, 
        "overall_official": {
            "affiliation": "Dermato-venerologisk Afdeling D42", 
            "last_name": "Merete H\u00e6dersdal, dr. med., ph.d.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Det danske sundhedsv\u00e6sen", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "VSS , POSAS, Appearance assessment-Evaluation of the scar by blinded investigator.", 
            "measure": "Scar Evaluation", 
            "safety_issue": "No", 
            "time_frame": "3 month following the 3rd treatment."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02050126"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "VSS assessment -Evaluation of the scar by blinded investigator.", 
                "measure": "Scar Evaluation.", 
                "safety_issue": "No", 
                "time_frame": "At base line , at the 3rd treatment and at the 1, 3 and 6 months follow-up"
            }, 
            {
                "description": "POSAS assessment by blinded Investigator and subject", 
                "measure": "POSAS assessment", 
                "safety_issue": "No", 
                "time_frame": "At base line , at the 3rd treatment and at the 1, 3 and 6 months follow-up"
            }, 
            {
                "description": "A High Definition Ultrasound (US) device will be used to generate a high resolution image of the skin layers of the treated and non-treated scar in order to measure and compare changes in scar thickness and uniformity.", 
                "measure": "Scar Thickness and Uniformity", 
                "safety_issue": "No", 
                "time_frame": "At base line, at the 3rd treatment and at the 1, 3 and 6 months follow-up"
            }, 
            {
                "description": "Colorimeter will be used for color measurement.", 
                "measure": "Scar color", 
                "safety_issue": "No", 
                "time_frame": "At base line, at the 3rd treatment and at the 1, 3 and 6 months follow-up."
            }, 
            {
                "description": "Histochemical analysis of scar tissue with different staining for analysis of changes following treatment:\nH&E staining and histology for collagen arrangement, epidermal rete ridges and measurement of scar depth\nCollagen type I and III staining\nElastin staining\nImmunohistochemistry for TGF-beta 1, 2, 3 and MMPs", 
                "measure": "Histochemical Changes in scar tissue", 
                "safety_issue": "No", 
                "time_frame": "Immediately before the 2nd, and 3rd treatment"
            }, 
            {
                "description": "Subject's satisfaction of the treatment using  a Satisfaction Scale as follows: None; Slight; Moderate; Good; Very Good.", 
                "measure": "Subject's satisfaction", 
                "safety_issue": "No", 
                "time_frame": "At the 3rd treatment and at the 1, 3 and 6 month follow-up"
            }
        ], 
        "source": "Lumenis Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lumenis Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}